Qbic
VC Fund
London, United Kingdom
Qbic is a VC fund in London focused on Health Care and Biotechnology. Qbic is the result of a lot of thinking, debating and sketching of what a city hotel could be; one that breaks the rules and makes people smile.An astonishing level of change has swept through the world over the last few years. But the hotel experience is no different than it’s ever been: stuffy, over-priced and lacking soul. They’re here tochange all that. they’re curious, imaginative and friendly, and they think there are lots of people just like us seeking a hotel with personality in the middle of the city.They believe in something better than what’s currently out there. A place that celebrates life rather than sucks life out of it. A hotel that’s built on creativity and a belief that you don’t have to accept the conventional. Somewhere that sends you away with fun stories and ideas, and is easy on your pocket.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Qbic invests in
Stages Qbic invests in
Countries Qbic invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $3.7M–$11M
- Series B
- $8.2M–$12M
Investment Focus
Industry
- Health Care 3 (43%)
- Biotechnology 3 (43%)
- AgTech 1 (14%)
- Medical 1 (14%)
- mHealth 1 (14%)
Stage
- Seed 3 (43%)
- Series B 2 (29%)
- Funding Round 1 (14%)
- Venture - Series Unknown 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Julie Fawcett
Chief Executive Officer & Board Member
|
Chief Executive Officer & Board Member | Total investments: 0 | Find email | |
|
Paul Lewis
Chief Financial Officer & Board Member
|
Chief Financial Officer & Board Member | Total investments: 0 | Find email | |
Philip Newborough
Partner
|
Partner | Total investments: 2 | Find email | |
|
Rekha T.
Chief Investment Officer
|
Chief Investment Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Axithra provides therapeutic medication monitoring and measures beta-lactam antibiotic concentrations in blood. | $10.7M / Seed / Sep 05, 2023 | ||
| Contributes to better healthcare thanks to its platform allowing access to structured, validated and anonymised Real World Data. | $3.7M / Seed / Mar 25, 2022 | ||
| moveUP develops and commercialise digital therapeutics solutions. Its closed loop system enables high compliance, better outcome and satisfaction. It uses continuously collected data to directly personalise the treatment of the patient. Its first therapy treats orthopaedic patients undergoing a joint surgery. It has CE medical device & ISO13485 certification. | $4.5M / Seed / May 24, 2021 | ||
| Accelleran is pioneering a disruptive approach to the delivery of cost-effective, carrier and mission-critical grade TDD and FDD Small Cell networks through its focus on software quality and partnerships with volume manufacturers.Accelleran provides LTE Small Cell software and LTE Small Cell product solutions which address the real-worldchallenges of volume deployment of Small Cells. We offer turnkey solutions and unique experience on the challenges of integrating cellular technology on low cost, yet powerful platforms and architectures. Accelleran offers its customers solid and dependable system solutions, backed by the support of our unparalleled expertise.Accelleran’s technology is genuinely independent from any HW platform and enables operators to invest once in the integration and validation of a common software base that can be deployed across different segments, platforms and Small Cell architectural approaches to enable a truly integrated HetNet. | $8.2M / Series B / May 05, 2021 | ||
| Pharmafluidics is a spin-off company of the Vrije Universiteit Brussel, aiming at developing integrated milli- to nano-engineered solutions for mixing, separation and reaction processes. Rooted in chemical engineering with an advanced know-how in micro-fabrication technology, our team specializes in developing high quality and tailor-made solutionsfor any problem in the chemical and life sciences industry potentially benefiting from miniaturization or fine material structuring. | $8.8M / Venture - Series Unknown / Jan 11, 2018 | ||
| Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium. | $11.6M / Series B / Mar 09, 2017 | ||
| Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium. | $5.5M / Jan 11, 2013 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Qbic invest in?
Qbic invests primarily in Health Care, Biotechnology and AgTech startups, most often at Seed and Series B stage. Most of the 7 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Qbic's check size?
Qbic typically joins rounds of $3.7M–$11M at Seed and $8.2M–$12M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Qbic participates in.
How do I contact Qbic?
Public channels for Qbic include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Qbic?
The team at Qbic includes Julie Fawcett (Chief Executive Officer & Board Member), Paul Lewis (Chief Financial Officer & Board Member) and Philip Newborough (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
